43 completed. 43 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 43 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
Follow Colchicine: new trials by email Literature Review of Colchicine trials Research Report on Colchicine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare ABP-745 Dose A, ABP-745 Dose B, Colchicine - Acute Gouty Arthritis, Gout Flare | Phase 2 | Completed | Atom Therapeutics Co., Ltd | 479 | 2025-08-26 | 2026-10-28 |
| EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL Colchicine 0.5 MG Oral Tablet - COVID - 19 | Phase 1 / Phase 2 | Completed | Zaeema Kanwal | 66 | 2025-02-24 | 2025-09-04 |
| Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR) Colchicine - Chronic Kidney Diseases, Renal Failure | Phase 2 | Completed | Hamilton Health Sciences Corporation | 96 | 2024-11-15 | 2026-08-13 |
| Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare Genakumab for injection, Colchicine - Acute Gout, Gout Flare | Phase 2 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 106 | 2023-07-21 | 2024-11-08 |
| A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202) Genakumab for injection, Colchicine - Gout, Gout Initiating Urate-loweringUrate-lowering Therapy | Phase 2 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 165 | 2023-07-20 | 2025-01-01 |
| Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Colchicine - HFpEF - Heart Failure With Preserved Ejection Fraction, Colchicine | Phase 1 / Phase 2 | Completed | I.M. Sechenov First Moscow State Medical University | 42 | 2022-12-15 | 2026-04-23 |
| Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage Colchicine Pill, Placebo - Intracranial Hemorrhages | Phase 2 | Completed | Population Health Research Institute | 100 | 2022-08-04 | 2026-09-01 |
| Effect of Colchicine on the Progression of Aortic Valve Stenosis - A Pilot Study Colchicine 0.6 mg, Placebo - Aortic Stenosis, Inflammation | Phase 2 / Phase 3 | Completed | Ottawa Heart Institute Research Corporation | 24 | 2022-07-01 | 2026-05-06 |
| COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS) Colchicine, Atorvastatin - Non ST Segment Elevation Acute Coronary Syndrome | Phase 2 | Completed | Azienda USL Toscana Centro | 182 | 2022-02-24 | 2024-07-16 |
| Colchicine in Patients Undergoing Coronary Artery Bypass Grafting After Acute Coronary Syndrome Colchicine - Coronary Artery Disease, Acute Coronary Syndrome | Phase 2 | Completed | University of Sao Paulo General Hospital | 100 | 2022-02-05 | 2026-03-03 |
| Colchicine to Suppress Inflammation and Improve Insulin Resistance in Adults and Adolescents With Obesity Colchicine, Placebo - Obesity, Insulin Resistance | Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 152 | 2021-11-08 | 2025-09-05 |
| Post-Ablation Pericarditis Reduction Study Colchicine - Atrial Fibrillation, Catheter Ablation | Phase 2 | Completed | St. Vincent Cardiovascular Research Institute | 248 | 2021-05-20 | 2022-11-08 |
| Post-Ablation Pericarditis Reduction Study (PAPERS) Colchicine - Atrial Fibrillation, Catheter Ablation | Phase 2 | Completed | St. Vincent Cardiovascular Research Institute | 248 | 2021-05-20 | 2024-12-12 |
| Effectiveness of Colchicine Among Patients With COVID-19 Infection Colchicine 0.5 MG, usual care treatment - Coronavirus Infection | Phase 2 | Completed | Hawler Medical University | 100 | 2021-05-08 | 2021-06-22 |
| Impact of Colchicine and Low-dose Naltrexone on COVID-19 Colchicine 0.6 mg, Naltrexone - Covid19 | Phase 2 | Completed | HealthPartners Institute | 142 | 2021-01-25 | 2023-07-25 |
| Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia Emtricitabine/tenofovir, Colchicine Pill, Rosuvastatin - COVID-19 | Phase 2 / Phase 3 | Completed | Universidad Nacional de Colombia | 650 | 2020-08-18 | 2021-08-12 |
| COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 Colchicine, Ruxolitinib 5 MG, Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] - COVID 19 | Phase 2 | Completed | Lomonosov Moscow State University Medical Research and Educational Center | 70 | 2020-05-08 | 2022-11-25 |
| Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19) Colchicine Tablets, Current care per UCLA treating physicians - COVID-19 | Phase 2 | Completed | University of California, Los Angeles | 93 | 2020-05-01 | 2022-11-03 |
| Colchicine Counteracting Inflammation in COVID-19 Pneumonia Colchicine - Coronavirus Infections, Pneumonia, Viral | Phase 2 | Completed | Azienda Ospedaliero-Universitaria di Parma | 193 | 2020-04-20 | 2022-07-20 |
| The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection Colchicine Tablets - COVID-19 | Phase 2 | Completed | Shahid Beheshti University of Medical Sciences | 80 | 2020-03-20 | 2022-01-28 |
Showing 20 of 43. Sign in to see all of them.
Gout (11) · COVID-19 (8) · Coronary Artery Disease (5) · Hyperuricemia (4) · Inflammation (4) · Acute Coronary Syndrome (3) · Atrial Fibrillation (3) · Atherosclerosis (2) · Carcinoma, Hepatocellular (2) · Coronavirus Infections (2) · Obesity (2) · Pericarditis (2) · Acquired Immunodeficiency Syndrome (1) · Acute Kidney Injury (1) · Amyotrophic Lateral Sclerosis (1)
Gilead Sciences (5) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Hamilton Health Sciences Corporation (2) · Johns Hopkins University (2) · Kaohsiung Medical University Chung-Ho Memorial Hospital (2) · St. Vincent Cardiovascular Research Institute (2) · Atom Therapeutics Co., Ltd (1) · Azienda Ospedaliero-Universitaria di Modena (1) · Azienda Ospedaliero-Universitaria di Parma (1) · Azienda USL Toscana Centro (1) · Dyve Biosciences, Inc. (1) · Hawler Medical University (1) · HealthPartners Institute (1) · Hospital Central "Dr. Ignacio Morones Prieto" (1)
United States (19) · Canada (7) · China (3) · Italy (3) · Russia (3) · Taiwan (3) · Colombia (2) · Georgia (2) · Iran (2) · Singapore (2) · Turkey (Türkiye) (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1)
Hejian Zou (2) · Jack A Yanovski, M.D. (2) · Parin J. Patel, MD (2) · Robert G Weiss, MD (2) · Alexandra Steinberg, MD, PhD (1) · Anastasia Shchendrygina (1) · Anna Toso, MD (1) · Arash Tehrani Banihashemi, MD, MPH (1) · Aristeidis Katsanos, MD (1) · Aryan MF Jalal (1) · Ashkan Shoamanesh, MD (1) · Bahar Sadeghi, MD (1) · Dan Delaney, PharmD (1) · Dashty Albustany, MBChB.FRCP (1)
PMID 34658014, PMID 16186437, PMID 23040570, PMID 24508207, PMID 25172965, PMID 26228647, PMID 32081221, PMID 32553209, PMID 32720823, PMID 33270311, PMID 15308692, PMID 15320751, PMID 16134130, PMID 19597921, PMID 20336760, PMID 20704622, PMID 21435708, PMID 23208422, PMID 24773578, PMID 25925674, PMID 26576054, PMID 26989892, PMID 27344959, PMID 27585965, PMID 27980008, PMID 29426008, PMID 29848361, PMID 30349811, PMID 30869182, PMID 30937899, PMID 30976418, PMID 31152038, PMID 31740368, PMID 31978293, PMID 32020029, PMID 32074550, PMID 32083985, PMID 32109013, PMID 32150618, PMID 32171740, PMID 32187464, PMID 32205204, PMID 32503620, PMID 32863171, PMID 33587443, PMID 34473343, PMID 34722661, PMID 34957385, PMID 35783822, PMID 36256671
R01HL120905 (1), R01HL125059 (1), ZIAHD000641-23 (1)